Taking into account the immune mechanistic nature of the CAR T cell intervention and its proven activity in patients with diffuse LBCL (DLBCL) with poor or favorable conventional tumor-related prognostic markers, such as bcl-2, bcl-6 and c-Myc status, we first hypothesized that dynamic patterns developing rapidly in the post-treatment TME distinguish responders and non-responders and, second, that certain characteristics of the tumor immune contexture, pre-treatment, may associate with CAR T cell treatment outcome. Here, BCL2 is linked to neoplasm.